Andrew J. Danford

Andrew J. Danford is a partner at Wilmer Cutler Pickering Hale & Dorr LLP (WilmerHale), where his practice focuses on complex intellectual property disputes, particularly in the life sciences and technology sectors. He has significant experience in biosimilar litigation under the Biologics Price Competition and Innovation Act (BPCIA) and patent cases under the Hatch-Waxman Act, representing innovator pharmaceutical clients. His technology experience also spans disputes involving smartphones, microprocessors, telecommunications networks, internet technologies, and video compression.

Danford is recognized for his balanced approach to patent litigation, representing both patentees and defendants. While his single tracked appearance is on the defendant side, his public profile details extensive experience advocating for patentees. For instance, he played a key role in helping Apple Inc. overturn a $506 million infringement judgment related to a microprocessor patent, effectively defending the company. Conversely, he has represented patentees such as Genentech in high-profile biosimilar litigation concerning a breast cancer therapy, and Bristol-Myers Squibb and Pfizer, achieving a complete victory in a major Hatch-Waxman case involving the drug Eliquis®, where patents were found valid and infringed. He also represented the patentee in multi-defendant Hatch-Waxman litigation concerning cholesterol-lowering drugs.

His litigation experience includes numerous bench and jury trials in federal district courts across Delaware, California, Texas, and Wisconsin, as well as appeals before the US Court of Appeals for the Federal Circuit. Danford is also active in post-grant proceedings, having represented clients in parallel inter partes review (IPR) proceedings before the Patent Trial and Appeal Board (PTAB) in biosimilar matters, including for Genentech's Herceptin.